[Risk of endometrial carcinoma in women receiving estrogens in menopause].

The incidence of endometrial cancer during the menopausal period as a result of therapy involving the use of estrogens, such as estrone, estradiol, and estriol, is examined on the basis of current literature and material obtained from international symposiums. This problem has normally been analyzed by a determination of the estrogen balance and metabolism. Indications linking estrogens with carcinoma have been in regard to the dosage and type of estrogen, and the length, nature (interrupted or continuous), and type (cyclical or not) of administration. The risk of endometrial carcinoma is found to increase accordingly with the length of treatment, and if it is uninterrupted. The risk is found to be diminished only in cases of cyclical therapy, with period interruptions. The alarming rates of endometrial cancer found in menopausal users of estrogens is noted to be primarily an American phenomenon, not noted with Polish preparations and therapeutic techniques.